Dear Colleagues, 

When combined with bioengineering approaches, human pluripotent stem cells hold great promise for a number of biomedical applications. Most of these applications fall into one of two general categories: cell-based modeling systems or regenerative medicine. In this Special Issue on “Bioengineering in Human Induced Pluripotent Stem Cells”, contributions tackling the many bioengineering challenges that are crucial for creating successful modeling systems and regenerative medicine approaches utilizing human-induced pluripotent stem cells (iPSCs) or human embryonic stem cells (hESCs) will be showcased.

Such modeling systems have helped further our understanding of healthy and disease states and supported improved drug testing platforms. More accurate modeling systems and high-throughput drug screening platforms have been developed by combining pluripotent stem cells with bioengineered cell culture approaches (biomimetic 3D culture systems, incorporating extracellular matrix (ECM) proteins, bioprinting, automation, etc.). These advancements, together with the ability to use human iPSCs in a patient-specific manner, have helped support a shift from personalized medicine to patient-specific therapies. However, challenges remain in the reproducibility, streamlining, and scale-up to make patient-specific therapies a viable option for most patients.

Considerable progress has been made in the field of regenerative medicine, which has focused on using iPSCs or hESCs clinically for repairing or replacing damaged cells or tissues. Key hurdles include developing scaffolds and other systems suitable for transplantation, clinical scale-up, shifting from 2D to 3D culture systems, and manufacturing demands. Most recently, the cells themselves are being bioengineered using genome editing techniques (e.g., CRISPR/Cas9) to enhance cellular performance.

Original research articles and reviews are welcome in all relevant areas of research.

Dr. Teisha J. Rowland
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• human induced pluripotent stem cells (iPSCs)
• human embryonic stem cells (hESCs)
• regenerative medicine
• organoids
• organ-on-a-chip
• bioreactor culture systems
• tissue bioengineering
• biomaterials
• biomimetic
• extracellular matrix (ECM)
• disease modeling
• drug discovery
• drug testing
• gene editing
• patient-specific therapies
• clinical translation
• transplantations